Allergan, Inc. News Headlines

AGN 
$225.02
*  
0.73
0.32%
Get AGN Alerts
*Delayed - data as of Jan. 28, 2015 13:57 ET  -  Find a broker to begin trading AGN now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    AGN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Novartis Successfully Expands Signifor Label in the U.S. - Analyst Blog
12/17/2014 4:45:00 AM - Investopedia


Actavis CEO to Remain After Allergan Merger
12/16/2014 8:33:00 AM - Dow Jones Business News


Actavis CEO Brent Saunders To Continue At Helm Upon Acquisition Of Allergan
12/16/2014 8:02:00 AM - RTT News


Brent Saunders faces challenge of running combined Actavis-Allergan
12/15/2014 7:37:00 PM - Dow Jones Business News


Top Healthcare Stocks for 2014
12/14/2014 11:03:14 AM - Motley Fool


Merck Reveals Data from Breast Cancer Study on Keytruda - Analyst Blog
12/11/2014 5:10:00 PM - Zacks.com


Roche (RHHBY) Presents Positive Data on Haemophilia Drug - Analyst Blog
12/10/2014 5:16:00 PM - Zacks.com


Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More
12/10/2014 12:17:00 PM - Seeking Alpha


Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
12/9/2014 3:15:00 PM - Zacks.com


Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog
12/8/2014 5:10:00 PM - Zacks.com


Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog
12/8/2014 4:35:00 PM - Zacks.com


Novartis (NVS) Presents Additional Data on Leukemia Drug - Analyst Blog
12/8/2014 3:30:00 PM - Zacks.com


Merck's New Oncology Product Positive in Early Study - Analyst Blog
12/8/2014 3:10:00 PM - Zacks.com


Is It Time to Buy This Growth Stock?
12/8/2014 9:43:02 AM - Motley Fool


The 3 Most Memorable Moments in Healthcare This Year
12/7/2014 3:02:02 PM - Motley Fool


Roche to Acquire California-based Ariosa Diagnostics - Analyst Blog
12/5/2014 6:47:00 PM - Zacks.com


Sanofi Buys Merck's Manufacturing Facility in Puerto Rico - Analyst Blog
12/5/2014 5:49:00 PM - Zacks.com


Activist Fund ValueAct Capital to Seek Up to $1.5 Billion From Investors -- Update
12/5/2014 11:29:00 AM - Dow Jones Business News


Sanofi's Priftin Gains U.S. Approval for Latent TB Indication - Analyst Blog
12/4/2014 4:45:00 PM - Zacks.com


Gilead Sciences: An Alpha Stock Through The Good And Bad Times
12/4/2014 3:14:00 PM - Seeking Alpha


Consumer Health Spending a Welcome Wrinkle for Allergan-Actavis Deal
12/4/2014 10:24:02 AM - Motley Fool


AstraZeneca's (AZN) Iressa Accepted for Review in the U.S. - Analyst Blog
12/3/2014 4:45:00 PM - Zacks.com


Cramer's Mad Money - Deckers Is About More Than Just Uggs (12/2/14)
12/3/2014 5:33:00 AM - Seeking Alpha


Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog
12/2/2014 6:45:00 PM - Zacks.com


U.S. Stock Mutual Funds Led Advance In November
12/2/2014 6:19:00 PM - Investor's Business Daily